193 results on '"Colonno, Richard"'
Search Results
2. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
3. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection
4. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
5. Targeting a Binding Pocket within the Trimer-of-Hairpins: Small-Molecule Inhibition of Viral Fusion
6. A Small Molecule HIV-1 Inhibitor That Targets the HIV-1 Envelope and Inhibits CD4 Receptor Binding
7. Human Immunodeficiency Virus Type 1 Viral Background Plays a Major Role in Development of Resistance to Protease Inhibitors
8. Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study.
9. Identification of I50L as the Signature Atazanavir (ATV)-Resistance Mutation in Treatment-Naive HIV-1-Infected Patients Receiving ATV-Containing Regimens
10. Utilization of in vitro Caco‐2 permeability and liver microsomal half‐life screens in discovering BMS‐488043, a novel HIV‐1 attachment inhibitor with improved pharmacokinetic properties
11. Long-Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis Infection
12. In vitro Synthesis of Messenger RNA by a Defective Interfering Particle of Vesicular Stomatitis Virus
13. Biochemical Studies on Capped RNA Primers Identify a Class of Oligonucleotide Inhibitors of the Influenza Virus RNA Polymerase
14. Methylation of Messenger RNA of Newcastle Disease Virus in vitro by a Virion-Associated Enzyme
15. Molecular Cloning and Complete Sequence Determination of RNA Genome of Human Rhinovirus Type 14
16. Evidence for the Direct Involvement of the Rhinovirus Canyon in Receptor Binding
17. Sequence-Specific Interaction of Tat Protein and Tat Peptides with the Transactivation-Responsive Sequence Element of Human Immunodeficiency Virus Type 1 in vitro
18. cDNA Cloning Reveals that the Major Group Rhinovirus Receptor on HeLa Cells is Intercellular Adhesion Molecule 1
19. Accumulation of Newly Synthesized mRNAs in Response to Human Fibroblast (β ) Interferon
20. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
21. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
22. Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir
23. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
24. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
25. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion
26. The effects of the Roche AMPLICOR HIV-1 MONITOR ® UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons
27. PPI-668, A Potent New Pan-Genotypic HCV NS5A Inhibitor: Phase 1 Efficacy and Safety: 1874
28. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy#
29. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance
30. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
31. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
32. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
33. Entecavir 2-year resistance update: no resistance observed in nucleoside-naïve patients and low frequency resistance emergence in lamivudine-refractory patients: 45
34. Preclinical Pharmacokinetics of a Novel HIV-1 Attachment Inhibitor BMS-378806 and Prediction of its Human Pharmacokinetics
35. Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus
36. Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold
37. Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients.
38. Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor
39. Genotypic and Phenotypic Analysis of Human Immunodeficiency Virus Type 1 Isolates from Patients on Prolonged Stavudine Therapy
40. Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors
41. Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs
42. LBP-12-Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers
43. LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
44. PS-073-Preclinical profile of HBV core protein inhibitor, ABI-H, a potent inhibitor of cccDNA generation in HBV infected cells
45. Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
46. Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns
47. Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability
48. Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment. 12. Structure–Activity Relationships Associated with 4-Fluoro-6-azaindole Derivatives Leading to the Identification of...
49. Inhibitors of Human ImmunodeficiencyVirus Type 1(HIV-1) Attachment 6. Preclinical and Human Pharmacokinetic Profilingof BMS-663749, a Phosphonooxymethyl Prodrug of the HIV-1 AttachmentInhibitor...
50. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.